The Flow Cytometry Laboratory (Flow Lab) was established by the University of Wisconsin Carbone Cancer Center (UWCCC) in 1988 to support the laboratory, translational and clinical research activities of our members. The mission of the Flow Lab is to provide state-of-the-art instrumentation, technical expertise, cutting edge and cost-effective services and high quality education programs to advance laboratory, translational and clinical cancer research through the use of flow cytometry and high content cell imaging. The Flow Lab currently provides services at two sites. The main laboratory is located at the Wisconsin Institutes for Medical Research (WIMR), on the west side of the UW-Madison campus and a satellite laboratory is operating at the McArdle Laboratory for Cancer Research (McArdle), on the central UW Madison campus. The Flow Lab maintains four benchtop flow cytometer analysis instruments, two high-speed sorting cytometers, a high-throughput bioimaging microscope, as well as a fluorescent microscope with camera and supporting instrumentation such as biosafety cabinets, centrifuges and incubators. The Flow Lab is staffed from 8;00am to 6;00pm Monday through Friday and instrumentation is available to trained users at all times. Through support from the Cancer Center Support Grant (CCSG), successful instrumentation grants, institutional funds and charges to users, the Flow Lab is able to provide the instrumentation and expertise needed to serve the diverse research needs of UWCCC members in areas relating to use of analytical flow cytometry, cell sorting and high content cell imaging.
The mission of the Flow Cytometry Laboratory is to provide state-of-the-art instruments, technical expertise, cutting edge services and high quality education programs to advance laboratory, translational and clinical cancer research through the use of flow cytometry and high content cell imaging.
|Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70|
|Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24|
|Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31|
|Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17|
|Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607|
|Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609|
|Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8|
|LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76|
|Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9|
|Ayvaci, Mehmet U S; Alagoz, Oguzhan; Chhatwal, Jagpreet et al. (2014) Predicting invasive breast cancer versus DCIS in different age groups. BMC Cancer 14:584|
Showing the most recent 10 out of 472 publications